FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors
出版年份 2021 全文链接
标题
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors
作者
关键词
FGFR1, Breast cancer, Endocrine resistance, Tyrosine kinase inhibitors
出版物
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1876, Issue 2, Pages 188595
出版商
Elsevier BV
发表日期
2021-07-23
DOI
10.1016/j.bbcan.2021.188595
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overcoming Endocrine Resistance in Breast Cancer
- (2020) Ariella B. Hanker et al. CANCER CELL
- Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
- (2020) Mónica Álvarez-Fernández et al. CANCER CELL
- The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
- (2020) Navid Sobhani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
- (2020) Young K. Chae et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer
- (2020) Pingping Mao et al. CLINICAL CANCER RESEARCH
- Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors
- (2020) Hiroshi Sootome et al. CANCER RESEARCH
- FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
- (2020) Susana Garcia-Recio et al. JOURNAL OF CLINICAL INVESTIGATION
- Extracellular matrix-bound FGF2 mediates estrogen receptor signaling and therapeutic response in breast cancer
- (2020) Josh W. DiGiacomo et al. MOLECULAR CANCER RESEARCH
- Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth
- (2020) María F. Chervo et al. ONCOGENE
- TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
- (2019) Maria Kalyukina et al. ChemMedChem
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- (2019) Luigi Formisano et al. Nature Communications
- Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
- (2019) Sylvia Grünewald et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
- (2019) Martin H. Voss et al. CLINICAL CANCER RESEARCH
- Insulin Receptor Associates with Promoters Genome-wide and Regulates Gene Expression
- (2019) Melissa L. Hancock et al. CELL
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer
- (2019) Joshua Z Drago et al. CLINICAL CANCER RESEARCH
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
- (2019) Richard D Kim et al. Cancer Discovery
- Breast cancer statistics, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
- (2019) Rina Hui et al. CLINICAL CANCER RESEARCH
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer
- (2018) Kevin Shee et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun
- (2018) Wei Shao et al. Protein & Cell
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrative clinical genomics of metastatic cancer
- (2017) Dan R. Robinson et al. NATURE
- Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
- (2017) Jennifer M. Giltnane et al. Science Translational Medicine
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
- (2017) Lukasz Turczyk et al. NEOPLASIA
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Evidence-Based Theory for Integrated Genome Regulation of Ontogeny-An Unprecedented Role of Nuclear FGFR1 Signaling
- (2016) Michal K. Stachowiak et al. JOURNAL OF CELLULAR PHYSIOLOGY
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
- (2016) A. Pearson et al. Cancer Discovery
- Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
- (2016) Celine Lefebvre et al. PLOS MEDICINE
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy
- (2015) Nobuyuki Itoh et al. Frontiers in Endocrinology
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
- (2014) J.- C. Soria et al. ANNALS OF ONCOLOGY
- FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
- (2014) M. W. Wynes et al. CLINICAL CANCER RESEARCH
- Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion
- (2014) S. J. Coleman et al. EMBO Molecular Medicine
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- Targeting Fibroblast Growth Factor Pathways in Prostate Cancer
- (2013) P. G. Corn et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours
- (2013) Brittany C Parker et al. JOURNAL OF PATHOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
- (2013) F. Malchers et al. Cancer Discovery
- High expression ofZNF703independent of amplification indicates worse prognosis in patients with luminal B breast cancer
- (2013) Inga Reynisdottir et al. Cancer Medicine
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior
- (2012) Athina-Myrto Chioni et al. JOURNAL OF CELL BIOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- (2011) Ezia Bello et al. CANCER RESEARCH
- Interaction between FGFR-2, STAT5, and Progesterone Receptors in Breast Cancer
- (2011) J. P. Cerliani et al. CANCER RESEARCH
- ZNF703is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium
- (2011) Daniel G. Holland et al. EMBO Molecular Medicine
- Mechanisms of FGFR3 actions in endocrine resistant breast cancer
- (2011) D.C. Tomlinson et al. INTERNATIONAL JOURNAL OF CANCER
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor Amplification
- (2010) A. A. Dudka et al. CANCER RESEARCH
- Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors
- (2010) Roshani R. Patel et al. EUROPEAN JOURNAL OF CANCER
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations
- (2009) E. D. Lew et al. Science Signaling
- Differential Interactions of FGFs with Heparan Sulfate Control Gradient Formation and Branching Morphogenesis
- (2009) H. P. Makarenkova et al. Science Signaling
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
- Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins
- (2008) Noriko Gotoh CANCER SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started